Inhibition of cytoplasmic GSK-3β increases cisplatin resistance through activation of Wnt/β-catenin signaling in A549/DDP cells

Cancer Letters

Volumn 336, Issue 1, 2013, Pages 231-239

  Gao, Yuan ^a,b   Liu, Zan ^a   Zhang, Xiuwei ^a   He, Jiani ^a   Pan, Yongqi ^a   Hao, Fengxia ^a   Xie, Lingling ^a   Li, Qingchang ^a   Qiu, Xueshan ^a   Wang, Enhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b LIAONING UNIVERSITY   (China)

Author keywords

Chemotherapy; Drug resistance; Glycogen synthase kinase 3 beta; Wnt catenin signaling

Indexed keywords

BETA CATENIN; CISPLATIN; GLYCOGEN SYNTHASE KINASE 3BETA; SERINE; SURVIVIN; TYROSINE; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; INHIBITION KINETICS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INHIBITORY CONCENTRATION 50; RNA, SMALL INTERFERING; WNT SIGNALING PATHWAY;

EID: 84878957147     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.005     Document Type: Article

References (44)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61(2):69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62(1):10-29.
3. Milanowski J., Szmygin-Milanowska K. Treatment of non-small cell lung cancer - where we are?. Pneumonol. Alergol. Pol. 2013, 81(1):55-60.
4. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Eastern cooperative oncology group, comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346(2):92-98.
5. Nishio K., Nakamura T. Conquering drug resistance in lung cancer. Nihon. Rinsho. 2000, 58(5):1041-1047.
6. Brabec V., Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist. Update 2002, 5(3-4):147-161.
7. McCubrey J.A., Steelman L.S., Abrams S.L., Lee J.T., Chang F., Bertrand F.E., Navolanic P.M., Terrian D.M., Franklin R.A., D'Assoro A.B., Salisbury J.L., Mazzarino M.C., Stivala F., Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 2006, 46:249-279.
8. Bouwman P., Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer 2012, 12(9):587-598.
9. Cui J., Jiang W., Wang S., Wang L., Xie K. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr. Pharm. Des. 2012, 18(17):2464-2471.
10. He B., Barg R.N., You L., Xu Z., Reguart N., Mikami I., Batra S., Rosell R., Jablons D.M. Wnt signaling in stem cells and non-small-cell lung cancer. Clin. Lung Cancer 2005, 7(1):54-60.
11. Teng Y., Wang X., Wang Y., Ma D. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem. Biophys. Res. Commun. 2010, 392(3):373-379.
12. Yeung J., Esposito M.T., Gandillet A., Zeisig B.B., Griessinger E., Bonnet D., So C.W. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010, 18(6):606-618.
13. Xu N., Shen C., Luo Y., Xia L., Xue F., Xia Q., Zhang J. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem. Biophys. Res. Commun. 2012, 425(2):468-472.
14. Zhang H., Zhang X., Wu X., Li W., Su P., Cheng H., Xiang L., Gao P., Zhou G. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway. Cancer Lett. 2012, 323(1):106-113.
15. Buechling T., Boutros M. Wnt signaling signaling at and above the receptor level. Curr. Top. Dev. Biol. 2011, 97:21-53.
16. Clevers H., Nusse R. Wnt/β-catenin signaling and disease. Cell 2012, 149(6):1192-1205.
17. Nusse R. Wnt signaling. Cold Spring Harb. Perspect. Biol. 2012, 4(5).
18. Kikuchi A., Yamamoto H., Sato A., Matsumoto S. New insights into the mechanism of Wnt signaling pathway activation. Int. Rev. Cell Mol. Biol. 2011, 291:21-71.
19. Krieghoff E., Behrens J., Mayr B. Nucleo-cytoplasmic distribution of β-catenin is regulated by retention. J. Cell Sci. 2006, 119(Pt 7):1453-1463.
20. Polakis P. Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol. 2012, 4(5).
21. Yamamoto H., Ngan C.Y., Monden M. Cancer cells survive with survivin. Cancer Sci. 2008, 99(9):1709-1714.
22. Kanwar R.K., Cheung C.H., Chang J.Y., Kanwar J.R. Recent advances in anti-survivin treatments for cancer. Curr. Med. Chem. 2010, 17(15):1509-1515.
23. Jin X., Li Q., Wu Q., Li P., Matsumoto Y., Furusawa Y., Gong L., Hao J., Dai Z. Radiosensitization by inhibiting survivin in human hepatoma HepG2 cells to high-LET radiation. J. Radiat. Res. 2011, 52(3):335-341.
24. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116(Pt 7):1175-1186.
25. Woodgett J.R. Regulation and functions of the glycogen synthase kinase-3 subfamily. Semin. Cancer Biol. 1994, 5(4):269-275.
26. Beurel E., Kornprobst M., Blivet-Van Eggelpoel M.J., Cadoret A., Capeau J., Desbois-Mouthon C. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis. Int. J. Oncol. 2005, 27(1):215-222.
27. Soto-Cerrato V., Viñals F., Lambert J.R., Kelly J.A., Perez-Tomas R. Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells. Mol. Cancer Ther. 2007, 6(1):362-369.
28. Cai G., Wang J., Xin X., Ke Z., Luo J. Phosphorylation of glycogen synthase kinase-3beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Int. J. Oncol. 2007, 31(3):657-662.
29. Wu J., Liao Q., He H., Zhong D., Yin K. TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin. Mol. Carcinog 2012, (Epub ahead of print).
30. Li C., Zhou C., Wang S., Feng Y., Lin W., Lin S., Wang Y., Huang H., Liu P., Mu Y.G., Shen X. Sensitization of glioma cells to tamoxifen-induced apoptosis by PI3-kinase inhibitor through the GSK-3β/β-catenin signaling pathway. PLoS ONE 2011, 6(10).
31. Zhang D., Ochi N., Takigawa N., Tanimoto Y., Chen Y., Ichihara E., Hotta K., Tabata M., Tanimoto M., Kiura K. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer Lett. 2011, 309(2):228-235.
32. Cetintas V.B., Kucukaslan A.S., Kosova B., Tetik A., Selvi N., Cok G., Gunduz C., Eroglu Z. Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines. Cell Biol. Int. 2012, 36(3):261-265.
33. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7(8):573-584.
34. Espada J., Calvo M.B., Díaz-Prado S., Medina V. Wnt signalling and cancer stem cells. Clin. Transl. Oncol. 2009, 11(7):411-427.
35. Kockeritz L., Doble B., Patel S., Woodgett J.R. Glycogen synthase kinase-3 - an overview of an over-achieving protein kinase. Curr. Drug Targets 2006, 7(11):1377-1388.
36. Song L., Xiong H., Li J., Liao W., Wang L., Wu J., Li M. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer. Clin. Cancer Res. 2011, 17(7):1839-1949.
37. Kumar A., Pandurangan A.K., Lu F., Fyrst H., Zhang M., Byun H.S., Bittman R., Saba J.D. Chemopreventive sphingadienes downregulate Wnt signaling via a PP2A/Akt/GSK3β pathway in colon cancer. Carcinogenesis 2012, 33(9):1726-1735.
38. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3(8):917-921.
39. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396(6711):580-584.
40. Yang D., Welm A., Bishop I.M. Cell division and cell survival in the absence of survivin. Proc. Natl. Acad. Sci. USA 2004, 101(42):15100-15105.
41. Samalin L., Nourry A., Llorca P.M. Lithium and anticonvulsants in bipolar depression. Encephale 2011, 7006(11):700054-700059.
42. Williams R., Ryves W.J., Dalton E.C., Eickholt B., Shaltiel G., Agam G., Harwood A.J. A molecular cell biology of lithium. Biochem. Soc. Trans. 2004, 32(Pt 5):799-802.
43. Beurel E., Kornprobst M., Blivet-Van Eggelpoel M.J., Ruiz-Ruiz C., Cadoret A., Capeau J., Desbois-Mouthon C. GSK-3β inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Exp. Cell Res. 2004, 300(2):354-364.
44. Johnson-Holiday C., Singh R., Johnson E.L., Grizzle W.E., Lillard J.W., Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J. Surg. Oncol. 2011, 9:46-52.